Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients

被引：0
|
作者：
Zhi-li Jin
Tao He
Li Peng
Xiao-yan Wu
Di Fan
Ming Chen
Yong-zhen Fan
Yuan-lin Guo
Zhi-bing Lu
Hai-rong Wang
机构：
[1] Zhongnan Hospital of Wuhan University,Department of Cardiovascular Medicine
[2] Wuhan University,Institute of Myocardial Injury and Repair
[3] Chinese Academy of Medical Sciences & Peking Union Medical College,Cardio
来源：
Current Medical Science | 2023年 / 43卷
关键词：
PCSK9 inhibitor; complex higher-risk and indicated patients; lipoprotein(a) level; low-density lipoprotein cholesterol level; 2-year cardiovascular event rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1206 / 1212
页数：6
相关论文
共 50 条
  • [1] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients
    Jin, Zhi-li
    He, Tao
    Peng, Li
    Wu, Xiao-yan
    Fan, Di
    Chen, Ming
    Fan, Yong-zhen
    Guo, Yuan-lin
    Lu, Zhi-bing
    Wang, Hai-rong
    CURRENT MEDICAL SCIENCE, 2023, 43 (06) : 1206 - 1212
  • [2] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
    Schwartz, Gregory G.
    Szarek, Michael
    Bittner, Vera A.
    Diaz, Rafael
    Goodman, Shaun G.
    Jukema, J. Wouter
    Landmesser, Ulf
    Lopez-Jaramillo, Patricio
    Manvelian, Garen
    Pordy, Robert
    Scemama, Michel
    Sinnaeve, Peter R.
    White, Harvey D.
    Steg, Ph Gabriel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (05) : 421 - 433
  • [3] PCSK9: Patients with high Lipoprotein (a) could benefit more
    Franke, Katharina
    AKTUELLE KARDIOLOGIE, 2019, 8 (03)
  • [4] Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
    Tardif, Jean-Claude
    Rheaume, Eric
    Rhainds, David
    Dube, Marie-Pierre
    EUROPEAN HEART JOURNAL, 2019, 40 (33) : 2782 - 2784
  • [5] Lipoprotein(a) and PCSK9 inhibition: clinical evidence
    Ruscica, Massimiliano
    Greco, Maria Francesca
    Ferri, Nicola
    Corsini, Alberto
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0L) : L53 - L56
  • [6] Effect of PCSK9 inhibition with alirocumab on lipoprotein(a) in patients with high risk of cardiovascular disease
    Safdar, S.
    Cramb, R.
    Dawson, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2017, 28 : E12 - E12
  • [7] PCSK9 inhibition in high-risk patients
    Zijlstra, Laurien E.
    Mooijaart, Simon P.
    Jukema, J. Wouter
    AGING-US, 2019, 11 (23): : 10791 - 10792
  • [8] PCSK9 Inhibition: Does Lipoprotein Size Matter?
    Si-Tayeb, Karim
    Cariou, Bertrand
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (11):
  • [9] Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
    O'Donoghue, Michelle L.
    Fazio, Sergio
    Giugliano, Robert P.
    Stroes, Erik S. G.
    Kanevsky, Estella
    Gouni-Berthold, Ioanna
    Im, KyungAh
    Pineda, Armando Lira
    Wasserman, Scott M.
    Ceska, Richard
    Ezhov, Marat V.
    Jukema, J. Wouter
    Jensen, Henrik K.
    Tokgozoglu, S. Lale
    Mach, Francois
    Huber, Kurt
    Sever, Peter S.
    Keech, Anthony C.
    Pedersen, Terje R.
    Sabatine, Marc S.
    CIRCULATION, 2019, 139 (12) : 1483 - 1492
  • [10] LIPOPROTEIN(A), PCSK9 INHIBITION AND CARDIOVASCULAR RISK: INSIGHTS FROM THE FOURIER TRIAL
    O'Donoghue, M.
    Giugliano, R.
    Keech, A.
    Kanevsky, E.
    Im, K.
    Lira, A.
    Pineda, A. Lira
    Somaratne, R.
    Sever, P.
    Pederson, T.
    Sabatine, M.
    ATHEROSCLEROSIS, 2018, 275 : E9 - E10
12345